Zeteletinib hemiadipate is an orally available, selective RET kinase inhibitor with nanomolar potency against RET and >300-fold selectivity over VEGFR2/KDR/Flk-1; it exhibits potent activity against wild-type RET, RET V804M/L gatekeeper mutants, and the most common oncogenic RET mutant M918T, demonstrating strong antitumor activity.